GLPwatch
Papers (10404)
Page 87 of 174, ranked by citation count.
- The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.
- Hes3 is expressed in the adult pancreatic islet and regulates gene expression, cell growth, and insulin release.
- Pharmacological treatment of obesity in adults in Norway 2004-2022.
- Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
- NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY.
- A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
- Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.
- Exendin-4 regulates the expression of the ATP-binding cassette transporter A1 via transcriptional factor PREB in the pancreatic β cell line.
- Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.
- Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin.
- Pancreatic imaging using an antibody fragment targeting the zinc transporter type 8: a direct comparison with radio-iodinated Exendin-4.
- Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis.
- Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
- Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care.
- No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.
- Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example.
- The comparison of three different molecular imaging methods in localization and grading of insulinoma.
- Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice.
- Feasibility of a Scale-down Production of [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4 in a Hospital Based Radiopharmacy.
- Fabrication and Evaluation of a pH-Responsive Nanocomposite-Based Colonic Delivery System for Improving the Oral Efficacy of Liraglutide.
- Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
- Exenatide reduces atrial fibrillation susceptibility by inhibiting hKv1.5 and hNav1.5 channels.
- Synthesis and pharmaceutical characterization of site specific mycophenolic acid-modified <i>Xenopus</i> glucagon-like peptide-1 analogs.
- GLP-1RA in the Real World: 1-year Compliance and Outcomes of Semaglutide use in Patients With or Without Previous History of Bariatric Surgery.
- Tirzepatide-Induced Rapid Weight Loss-Related Thyrotoxicosis.
- Exenatide reduces cardiomyocyte apoptosis by stimulating adiponectin secretion and activating APPL1-AMPK-PPARα axis.
- The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management.
- Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus.
- Use of exenatide and liraglutide in Denmark: a drug utilization study.
- Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents.
- The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.
- Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
- Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus.
- Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?
- Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review.
- An unusual case of a generalised cutaneous drug reaction to liraglutide.
- PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats.
- Exenatide as a novel weight loss modality in patients without diabetes.
- Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice.
- Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
- [Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].
- A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
- Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
- Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis.
- Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis.
- Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review.
- Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes.
- Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes.
- Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.
- Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs.
- Evaluation of glucagon-like peptide-1 receptor expression in nondiabetic and diabetic atherosclerotic mice using PET tracer <sup>68</sup>Ga-NODAGA-exendin-4.
- The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome.
- Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
- Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease.
- Triple Agonism Based Therapies for Obesity.
- Change in HbA<sub>1c</sub> Across the Baseline HbA<sub>1c</sub> Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.
- Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.
- Liraglutide protects β-cell function by reversing histone modification of Pdx-1 proximal promoter in catch-up growth male rats.
- Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis.
- Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.